Chronic Traumatic Encephalopathy (CTE)
No Results
No Results
processing….
Chronic Traumatic Encephalopathy (CTE) is a neurodegenerative disorder thought to be associated with exposure to repetitive head trauma. CTE is characterized neuropathologically by hyerphosopholarated tau (p- tau) deposition throughout the brain. The first reported clinical cases were described in boxers in the early 1900’s and described as “punch drunk” and since that time the terminology has evolved and is currently referred to as Chronic Traumatic Encephalopathy or “CTE.” Over the last decade, there has been increased awareness of the long term effect of mild traumatic brain injury (mTBI) in both the military and sports populations. Clinically, these individuals may present with constellation of chronic symptoms including mood, cognitive, behavioral and motor disturbances. A definitive diagnosis of CTE is made by post mortem macroscopic and histopathological accumulation of p-tau. Genetic influences such as Apolipoprotein E ε4 (APOE ε4) have been suggested to increase susceptibility to CTE after repetitive head trauma. [1] Future studies for clinical studies should focus on identification of diagnostic tools such as biomarkers, advanced neuroimaging, and neuropsychological testing to provide a diagnosis for CTE.
Traumatic Brain Injury (TBI) is a major health concern that is a leading cause of mortality, morbidity, and disability worldwide. Annually, in the United Sates there are over 1.7 million cases TBI of varying severities, ranging from mild to severe TBI. [2] In addition, with the recent US military conflicts, TBI has been deemed the “signature injury” of Operation Iraqi Freedom (OIF), Operation Enduring Freedom (OEF), and Operation New Dawn (OND), affecting up to 20% of all service members deployed in theatre with more than 339,000 TBIs reported in OIF/OEF/OND between 2000 and 2015, [3] over 75% of which are mild. [4]
TBI is defined as an alteration in brain function, or other evidence of brain pathology, caused by an external force leading to permanent or temporary impairment of cognitive, physical, and psychosocial functions. [5] TBI can be classified as mild, moderate, or severe, based on initial Glasgow coma scale (GCS), [6] duration of loss of consciousness, and duration of post-traumatic amnesia. [7]
Mild TBI or concussion can result in changes in cognitive function. Athletes and trauma patients often report diverse physical, behavioral, cognitive and emotional symptoms in the initial days and weeks following the injury. The most frequently endorsed symptoms include headaches, fatigue, attention/concentration, irritability, and dizziness. Most mTBI patients appear to recover within the first 2 weeks after injury, though there are a few where the symptoms evolve into a more persistent pattern (> 3 months). Subconcussive events or subclinical concussion results when impact to the head does not result in the clinical signs or symptoms of a concussion but it postulated that repetitive subclincal concussions can have a “deleterious” effect. [8] Repetitive closed head injury occurs in a wide variety of contact sports, including American football, hockey, soccer, lacrosse with thousands of subconcussive hits during the course of a single season.
The effects of single or multiple TBIs in later-life are poorly understood, particularly in mild TBI (mTBI). Recent studies suggest that even mTBI can lead to an increased risk of later-life cognitive impairment and neurodegenerative disease, especially when repeated injuries are involved. [9, 10, 11]
Table. (Open Table in a new window)
Geddes et al. examined five young adult brains and found neurofibrillary tangles and neuropil threads located adjacent to blood vessels in the absence of A beta amyloid. [20]
A study by Mez et al diagnosed CTE in 177 (78%) of 202 samples from deceased American football players. The samples included 111 former NFL players of which, 110 (99%) were diagnosed with CTE. The study also found that among the 26 participants diagnosed with mild CTE, 96% had behavioral or mood symptoms or both, 85% had cognitive symptoms, and 33% had signs of dementia. In the 84 participants diagnosed with severe CTE, 89% had behavioral or mood symptoms, 95% had cognitive symptoms, and 85% had signs of dementia. [31]
CTE is a chronic slowly progressive disease which can begin years to decades after acute exposure and recovery from repetitive head trauma and is distinct from persistent postconcussion symptoms.
Clinically, CTE is thought to be divided into three categories of impairment including: neuropsychiatric (increased impulsivity, explosivity, violence, rage, depression, apathy, substance abuse, suicidal behavior), cognitive (impaired attention, executive function, memory) and motor (Parkinsonism, dysphagia, dysarthria, poor coordination).
The early symptoms of CTE include short-term memory problems, irritability, executive function impairments, depression, emotional lability, impulse/anger control, suicidal behaviors and substance abuse. In later stages CTE can progress to worsening memory and executive function, worsening aggression, motor impairments and dementia. Stern et al suggests there are two major presentations of CTE with one being a behavior/mood variant occurring at a younger age (mean age 35) and the other being a cognitive variant occurring at an older age (mean age 60). [32]
The neuropathology of CTE can be broken up into gross and microscopic changes. The gross neuropathologic change in early CTE, if any, is mild enlargement of the fontal and temporal horns of the lateral and third ventricles. In advanced CTE gross changes include gray and white matter atrophy of the frontal and temporal lobes, decreased brain weight, enlargement of the fontal and temporal horns of the lateral and third ventricles, cavum pellucidum with fenestrations, atrophy of the thalamus, hypothalamus and mamillary bodies, thinning of the corpus callosum, and pallor of the locus coeruleus and substantia nigra.
McKee at al [26] established pathological staging criteria (I – IV) for CTE based on 85 subjects with history of repetitive head trauma and evidence of CTE. The criteria are based on location, pattern and pathological progression of tau accumulation. Stage I is characterized by isolated perivascular focal epicenters of p-tau neurofibrillary tangles and neuropil neurites, which is, localized to the sulcal depths of the cerebral cortex. Stage II is characterized by perivascular multiple epicenters of p-tau neurofibrillary tangles and neuropil neurites at the sulcal depths of the cerebral cortices. Stage III is characterized by widespread dense p- tau located in the frontal, septal, temporal. Stage IV is the most severe and advanced stage with widespread tau accumulation in the diencephalon, brain stem and cerebellum.
Microscopic neuropathology of CTE is characterized by deposition of hyperphosphorylated tau (p-tau) as neurofibrillary tangles, neuropil threads and astrocytic tangles. Tau is a protein that modulates the stability of axonal microtubules and maintains the shape of the neuron. The deposition of tau is seen in normal aging and as a feature of Alzheimer’s and other neurodegenerative disorders, but CTE has a distinct pattern and location of tau deposition and is pathognomic for CTE.
The preliminary NINDS/NIBIB consensus panel criteria required for pathologic diagnosis of CTE is: “The pathognomic lesion consists of p-tau aggregates in neurons, astrocytes, and cell processes around small vessels in an irregular pattern at the depths of the sulci.” In addition, the consensus panel provided supportive neuropathological features of CTE but that are were nonspecific for CTE. [33]
CTE has also been characterized by widespread TDP-43 proteinopathy in more than 80% of patients with CTE. [34] TDP-43 is involved in regulating translation in mitochondrial RNA in the brain. It has been associated with the physiological response to traumatic axotomy. [35] Blood levels of TDP-43 are elevated in association with a variety of neurodegenerative conditions, to include frontotemporal lobar degenerations, amyotrophic lateral sclerosis (ALS) and Alzheimer’s Disease. In some cases the TDP-43 proteinopathy extends to involve the spinal cord and may present as motor neuron disease similar to ALS. As in the case of tau, TDP-43 fibrillaries accumulate at anatomical points of geometric inflection in the brains of CTE subjects. Given that trauma focuses deformation forces in these areas, it is highly plausible that TDP-43 accumulation is in contact with the compromised microvasculature and, as such, would be present in the blood of trauma patients with latent CTE.
Beta-amyloid (Aβ) peptides have diagnostic and prognostic utility for a broad number of neurodegenerative disorders and can be found in 52% of individuals with CTE. [36] Aβ plaques are common immediately after TBI, [24] and Aβ continues to accumulate in traumatized axons that survive. [37] When Aβ plaques are present in CTE predominantly in a fibrillary form that resembles AD pathology more than acute TBI, but more diffuse and less dense than Alzheimer’s. Importantly, diffuse, widespread fibrillary Aβ accumulation resembles CTE pathology. [38]
Possession of the APOE-ε4 allele is a risk factor for dementia. [39] Carriers may have altered brain activity, even at a young age. [40] Long-term, but not short-term, effects of TBI may be influenced by APOE. APOE was not associated with poorer neuropsychological performance 1 month after mild or moderate TBI. [41] However, TBI was found to increase AD risk of APOE 10-fold. [42] Environmental factors, in particular multiple concussions, may influence the effects of APOE. Boxers with the APOE-ε4 allele who had participated in many bouts were more likely to have CTE, while the allele was not a risk factor in boxers who had only experienced a few fights. [21]
Structural neuroimaging such as CT and MRI are non-specific for CTE. Currently, there are no validated advanced neuroimaging techniques to provide a confirmatory diagnosis of CTE. Positron emission tomography (PET) ligands for p-tau, diffuse tensor imaging (DTI), magnetic resonance spectroscopy and functional MRI may have some potential benefit in the future.
Currently, there are no fluid biomarkers that can predict the presence of CTE.
DeKosky ST, Ikonomovic MD, Gandy S. Traumatic brain injury–football, warfare, and long-term effects. N Engl J Med. 2010 Sep 30. 363 (14):1293-6. [Medline].
Faul M, Xu L, Wald MM, Coronado VG. Traumatic Brain Injury in the United States. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2010. [Full Text].
DoD Worldwide Numbers for TBI. Defense and Veterans Brain Injury Center. Available at http://dvbic.dcoe.mil/dod-worldwide-numbers-tbi. Accessed: March 28, 2016.
Fischer H. A Guide to U.S. Military Casualty Statistics. Congressional Research Service. August 7, 2015. [Full Text].
Menon DK, Schwab K, Wright DW, Maas AI, Demographics and Clinical Assessment Working Group of the International and Interagency Initiative toward Common Data Elements for Research on Traumatic Brain Injury and Psychological Health. Position statement: definition of traumatic brain injury. Arch Phys Med Rehabil. 2010 Nov. 91 (11):1637-40. [Medline].
Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974 Jul 13. 2 (7872):81-4. [Medline].
Stein SC, Spettell C. The Head Injury Severity Scale (HISS): a practical classification of closed-head injury. Brain Inj. 1995 Jul. 9 (5):437-44. [Medline].
Bailes JE, Petraglia AL, Omalu BI, Nauman E, Talavage T. Role of subconcussion in repetitive mild traumatic brain injury. J Neurosurg. 2013 Nov. 119 (5):1235-45. [Medline].
Gavett BE, Stern RA, McKee AC. Chronic traumatic encephalopathy: a potential late effect of sport-related concussive and subconcussive head trauma. Clin Sports Med. 2011 Jan. 30 (1):179-88, xi. [Medline].
Guskiewicz KM, Marshall SW, Bailes J, McCrea M, Cantu RC, Randolph C, et al. Association between recurrent concussion and late-life cognitive impairment in retired professional football players. Neurosurgery. 2005 Oct. 57 (4):719-26; discussion 719-26. [Medline].
Plassman BL, Havlik RJ, Steffens DC, Helms MJ, Newman TN, Drosdick D, et al. Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias. Neurology. 2000 Oct 24. 55 (8):1158-66. [Medline].
Martland HS. Punch Drunk. JAMA. 1928. 91(15):1103-1107.
Parker HL. Traumatic Encephalopathy (`Punch Drunk’) of Professional Pugilists. J Neurol Psychopathol. 1934 Jul. 15 (57):20-8. [Medline].
Millspaugh, JA. Dementia pugilistica. US Naval Med Bull. 1937. 35:297-303.
Critchley M. Punch-Drunk Syndromes: The Chronic Traumatic Encephalopathy of Boxers. Maloin, Paris: Hommage a Clovis Vincent; 1949.
Roberts AH. Brain damage in boxers: A study of the prevalence of traumatic encephalopathy among ex-professional boxers. London: Pitman Medical & Scientific Pub. Co.; 1969.
Corsellis JA, Bruton CJ, Freeman-Browne D. The aftermath of boxing. Psychol Med. 1973 Aug. 3 (3):270-303. [Medline].
Hof PR, Knabe R, Bovier P, Bouras C. Neuropathological observations in a case of autism presenting with self-injury behavior. Acta Neuropathol. 1991. 82 (4):321-6. [Medline].
Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI. Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1994 Apr. 57 (4):419-25. [Medline].
Geddes JF, Vowles GH, Nicoll JA, Révész T. Neuronal cytoskeletal changes are an early consequence of repetitive head injury. Acta Neuropathol. 1999 Aug. 98 (2):171-8. [Medline].
Jordan BD. Chronic traumatic brain injury associated with boxing. Semin Neurol. 2000. 20 (2):179-85. [Medline].
Omalu BI, DeKosky ST, Minster RL, Kamboh MI, Hamilton RL, Wecht CH. Chronic traumatic encephalopathy in a National Football League player. Neurosurgery. 2005 Jul. 57 (1):128-34; discussion 128-34. [Medline].
Omalu BI, DeKosky ST, Hamilton RL, Minster RL, Kamboh MI, Shakir AM, et al. Chronic traumatic encephalopathy in a national football league player: part II. Neurosurgery. 2006 Nov. 59 (5):1086-92; discussion 1092-3. [Medline].
McKee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budson AE, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol. 2009 Jul. 68 (7):709-35. [Medline].
Omalu BI, Hamilton RL, Kamboh MI, DeKosky ST, Bailes J. Chronic traumatic encephalopathy (CTE) in a National Football League Player: Case report and emerging medicolegal practice questions. J Forensic Nurs. 2010 Spring. 6 (1):40-6. [Medline].
McKee AC, Stern RA, Nowinski CJ, Stein TD, Alvarez VE, Daneshvar DH, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013 Jan. 136 (Pt 1):43-64. [Medline].
Gardner A, Iverson GL, McCrory P. Chronic traumatic encephalopathy in sport: a systematic review. Br J Sports Med. 2014 Jan. 48 (2):84-90. [Medline].
Montenigro PH, Baugh CM, Daneshvar DH, Mez J, Budson AE, Au R, et al. Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome. Alzheimers Res Ther. 2014. 6 (5):68. [Medline].
Mez J, Solomon TM, Daneshvar DH, et al. Assessing clinicopathological correlation in chronic traumatic encephalopathy: rationale and methods for the UNITE study. Alzheimers Res Ther. 2015 Oct 12. 7 (1):62. [Medline].
Huber BR, Alosco ML, Stein TD, et al. Potential Long-Term Consequences of Concussive and Subconcussive Injury. Physical Medicine and Rehabilitation Clinics of North America. 2016.
Mez J, Daneshvar DH, Kiernan PT, et al. Clinicopathological Evaluation of Chronic Traumatic Encephalopathy in Players of American Football. JAMA. 2017. 318(4):360-370.
Stern RA, Daneshvar DH, Baugh CM, Seichepine DR, Montenigro PH, Riley DO, et al. Clinical presentation of chronic traumatic encephalopathy. Neurology. 2013 Sep 24. 81 (13):1122-9. [Medline].
McKee AC, Cairns NJ, Dickson DW, Folkerth RD, Keene CD, Litvan I, et al. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol. 2016 Jan. 131 (1):75-86. [Medline].
McKee AC, Gavett BE, Stern RA, Nowinski CJ, Cantu RC, Kowall NW, et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2010 Sep. 69 (9):918-29. [Medline].
Moisse K, Mepham J, Volkening K, Welch I, Hill T, Strong MJ. Cytosolic TDP-43 expression following axotomy is associated with caspase 3 activation in NFL-/- mice: support for a role for TDP-43 in the physiological response to neuronal injury. Brain Res. 2009 Nov 3. 1296:176-86. [Medline].
Stein TD, Montenigro PH, Alvarez VE, Xia W, Crary JF, Tripodis Y, et al. Beta-amyloid deposition in chronic traumatic encephalopathy. Acta Neuropathol. 2015 Jul. 130 (1):21-34. [Medline].
Smith DH, Chen XH, Iwata A, Graham DI. Amyloid beta accumulation in axons after traumatic brain injury in humans. J Neurosurg. 2003 May. 98 (5):1072-7. [Medline].
Johnson VE, Stewart W, Smith DH. Widespread τ and amyloid-β pathology many years after a single traumatic brain injury in humans. Brain Pathol. 2012 Mar. 22 (2):142-9. [Medline].
Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007. 29 (1-2):125-32. [Medline].
Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, et al. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci U S A. 2009 Apr 28. 106 (17):7209-14. [Medline].
Han SD, Drake AI, Cessante LM, Jak AJ, Houston WS, Delis DC, et al. Apolipoprotein E and traumatic brain injury in a military population: evidence of a neuropsychological compensatory mechanism?. J Neurol Neurosurg Psychiatry. 2007 Oct. 78 (10):1103-8. [Medline].
Mckee AC, Daneshvar DH. The neuropathology of traumatic brain injury. Handb Clin Neurol. 2015. 127:45-66. [Medline].
Geddes et al. examined five young adult brains and found neurofibrillary tangles and neuropil threads located adjacent to blood vessels in the absence of A beta amyloid. [20]
A study by Mez et al diagnosed CTE in 177 (78%) of 202 samples from deceased American football players. The samples included 111 former NFL players of which, 110 (99%) were diagnosed with CTE. The study also found that among the 26 participants diagnosed with mild CTE, 96% had behavioral or mood symptoms or both, 85% had cognitive symptoms, and 33% had signs of dementia. In the 84 participants diagnosed with severe CTE, 89% had behavioral or mood symptoms, 95% had cognitive symptoms, and 85% had signs of dementia. [31]
David Xavier Cifu, MD The Herman J Flax, MD, Professor and Chairman, Department of Physical Medicine and Rehabilitation, Virginia Commonwealth University School of Medicine; National Director, PM&R Services, Department of Veterans Affairs
David Xavier Cifu, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, Brain Injury Association of America, American Congress of Rehabilitation Medicine, American Medical Association, Association of Academic Physiatrists, National Stroke Association
Disclosure: Nothing to disclose.
Blessen C Eapen, MD Section Chief of Polytrauma, Rehabilitation Center, South Texas Veterans Health Care System; Adjunct Assistant Professor, Department of Rehabilitation Medicine, University of Texas Health Science Center at San Antonio School of Medicine
Blessen C Eapen, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Congress of Rehabilitation Medicine, Association of Academic Physiatrists, International Brain Injury Association
Disclosure: Nothing to disclose.
William F Carne, PhD Associate Professor, Department of Physical Medicine and Rehabilitation, VCU-MCV University Health System; Consulting Psychologist, McGuire Veterans Medical Center
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Kathleen Roarty Senior Production Manager, Medscape Reference
Disclosure: Nothing to disclose.
Craig C Young, MD Professor, Departments of Orthopedic Surgery and Community and Family Medicine, Medical Director of Sports Medicine, Medical College of Wisconsin
Craig C Young, MD is a member of the following medical societies: American Academy of Family Physicians, American College of Sports Medicine, American Medical Society for Sports Medicine, Phi Beta Kappa
Disclosure: Nothing to disclose.
Chronic Traumatic Encephalopathy (CTE)
Research & References of Chronic Traumatic Encephalopathy (CTE)|A&C Accounting And Tax Services
Source
0 Comments